Agilent Technologies, Inc. (A) Earnings Call Transcripts

Agilent Technologies, Inc.'s Latest Earnings Call - Q3 FY2026

In Q3 2026, Agilent Technologies reported strong financial results with revenue of $1.88 billion, reflecting a 7.3% core growth, exceeding guidance by 140 basis points. Earnings per share (EPS) reached $1.56, surpassing the high end of guidance by $0.06, and representing a year-over-year growth of 14%. Management raised full-year revenue guidance to a range of $7.49 billion to $7.51 billion, indicating a core growth of 5.8% to 6%, and increased EPS expectations to $6.18 to $6.21, up $0.15 from prior forecasts.

Reported metrics

Guidance from management

Agilent expects full-year revenue of $7.49 billion to $7.51 billion, indicating a core growth of 5.8% to 6%. EPS guidance was raised to $6.18 to $6.21, reflecting strong operational performance.

What management said

Yes. Thanks, Jack. I'll pass it over to Adam here in a second. But first of all, really pleased with the performance of nearly 30% growth, which was really within our expectations and moving along nicely. But Adam, do you want to add some detail on that?

Yes. So in general terms, we don't break out the CDMO business. But in general terms, the way we think about it is it should be roughly aligned to our broader business when it's running at full capacity. Then if you think about next year, especially as we're bringing on Train C, we'll be hiring staff in advance, and we'll start depreciating the facility in the early part of the year and then starting to get revenue l...

What analysts pressed on

Analysts expressed concerns regarding the sustainability of growth in the diagnostics segment, which grew 6% but was below expectations. There were also questions about the visibility and timing of the CDMO business's growth into 2027.

Main topics on the call

• Revenue Growth Acceleration — Agilent's Q3 revenue of $1.88 billion grew 7.3% on a core basis, exceeding guidance. CEO Padraig McDonnell stated, "Our results clearly demonstrate the sustained momentum unlocked by our exceptional commercial and operat...
• Strong Performance in Pharma — Pharma revenue grew 12%, well above expectations. Management noted, "Our advanced therapeutics division grew nearly 30%," reflecting strong demand and execution.
• China Market Strength — China revenue grew 9%, significantly above flat expectations. McDonnell highlighted, "We delivered this performance despite minimal China stimulus benefit and see the momentum continuing into year-end."
• Operating Margin Expansion — Operating margin reached 28.3%, including a $20 million tariff refund. Excluding this, the margin was 27.2%, 80 basis points above guidance, showcasing strong operational leverage.

Read the full Agilent Technologies, Inc. transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 77 Agilent Technologies, Inc. earnings call transcripts on record, spanning January 14, 2020 to August 26, 2026. Based on this history, Agilent Technologies, Inc. reports quarterly. The most recent call on file is dated August 26, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

A

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Life Sciences Tools and Services

Calls on record

77

First call

January 14, 2020

Most recent

August 26, 2026

Reporting cadence

quarterly